Fig. 2

Base case cost-effectiveness results by region. ABR: RSVpreF, HR: high risk, ICER: incremental cost-effectiveness ratio, MR: medium risk, NIRS: nirsevimab, PVZ: palivizumab, QALY: quality-adjusted life year. Costs and QALYs are per infant. ICERs are measured in $/QALY. Red circles indicate the most cost-effective strategy